In this issue:
Biologics use and risk of serious infection
Ixekizumab vs guselkumab for moderate-to-severe plaque psoriasis
Comorbidities and response to biologics
Two-year treatment patterns with ixekizumab vs secukinumab
Predictors of hepatitis B and C virus reactivation after biologics
Tacrolimus ointment + dupilumab for atopic dermatitis
Work ability in atopic dermatitis patients receiving dupilumab
Predictors of lack of response to adalimumab in moderate-to severe psoriasis
Biologics and small molecules for hidradenitis suppurativa
Time to relapse of plaque psoriasis after biologic discontinuation
Please login below to download this issue (PDF)